Key result
Ticagrelor-to-clopidogrel de-escalation 1 month post-PCI cuts net clinical events ~46% in patients under 75.
Why the study?
The clinical effects of dual antiplatelet therapy de-escalation after acute myocardial infarction may differ by age, but this has not been clearly evaluated.
Does de-escalation from ticagrelor to clopidogrel improve net clinical outcomes in stabilized patients 1 month after PCI for acute myocardial infarction, and does this effect vary by age?
RCT (n=2,697)
Open-label
Randomly allocated
Yes
Does de-escalation from ticagrelor to clopidogrel improve net clinical outcomes in stabilized patients 1 month after PCI for acute myocardial infarction, and does this effect vary by age?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This study was conducted only in South Korea. However, although the prevalence of the CYP2C19 loss-of-function allele is significantly higher in Koreans than in other ethnic groups, this study showed the clinical safety of switching in this population, suggesting the potential of applying this de-escalation strategy to other ethnic groups.”
“We have shown that, in patients who have had a heart attack and who've been treated with newer-generation stents and guideline-recommended medical therapy, de-escalation of DAPT by switching from ticagrelor to clopidogrel is completely safe and more effective than continuing to treat patients with ticagrelor.”
“I think this is going to have major implications for how we practice in taking care of our patients after acute MI. The fact is that many of us here in the States use this strategy both for cost reasons, for tolerability reasons, and for safety reasons. And what your study has shown us is that what we are already doing in the absence of great evidence appears to be both a safe and effective strategy. So I'm very pleased to see these results and I expect that this will further lend credence to what we are already doing certainly in the United States.”
Antiplatelet de-escalation from ticagrelor to clopidogrel significantly improved net clinical outcomes without excess ischemic risk in stabilized post-PCI patients aged <75 years, though limited power makes the safety and efficacy in patients ≥75 years uncertain.
Background The clinical effects of dual antiplatelet therapy de-escalation after acute myocardial infarction may differ by age. We evaluated whether the efficacy and safety of de-escalation from ticagrelor to clopidogrel differed by age in stabilized patients after percutaneous coronary intervention (PCI). Patients and methods This was a prespecified secondary analysis of the TALOS-AMI randomized trial. Patients event-free 1 month after PCI receiving aspirin–ticagrelor were randomly allocated to de-escalation (aspirin–clopidogrel) or continuation (aspirin–ticagrelor). The primary net clinical endpoint was a composite of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) and Bleeding Academic Research Consortium types 2, 3, or 5 bleeding at 1 year. Results We included 2697 participants (mean age 60.0 ± 11.4 years; 16.8% women). Among patients aged <75 years (*n* = 2376), de-escalation reduced the primary net clinical endpoint (4.1% vs. 7.2%; adjusted hazard ratio (aHR), 0.54 [95% CI, 0.38–0.77]) and bleeding (2.8% vs. 4.9%; aHR, 0.54 [0.35–0.82]). Among patients aged ≥75 years, no significant differences were observed for the primary endpoint (6.4% vs. 11.6%; aHR0.54 [0.25–1.17]) or bleeding (3.2% vs. 7.9%; aHR, 0.41 [0.15–1.15]). Interaction testing showed no treatment effect modification by age for the primary endpoint (*p* for interaction = 0.978), MACE (*p* = 0.585), or BARC bleeding (*p* = 0.597). Among patients aged ≥75 years, 14/18 bleeding events occurred within 180 days. Conclusions Among stabilized, event-free patients 1 month after PCI, no significant age–treatment interaction was observed; therefore, the efficacy and safety of de-escalation in older adults (≥75 years) remain uncertain. Trial registration: ClinicalTrials.gov (NCT02018055).
No takes yet. Share an insight, caveat, or question.
Bu et al. (2026) conducted an RCT in Acute myocardial infarction (AMI) (n=2,697). De-escalation to aspirin and clopidogrel vs. Continuation of aspirin and ticagrelor was evaluated on Primary net clinical endpoint (composite of cardiovascular death, myocardial infarction, stroke, and BARC type 2, 3, or 5 bleeding) in patients aged <75 years (aHR 0.54, 95% CI 0.38-0.77, p=<0.001). De-escalation from ticagrelor to clopidogrel 1 month after PCI reduced the primary net clinical endpoint by 46% in patients aged <75 years, with no significant age-treatment interaction observed overall.
Synapse has enriched 10 related papers. Consider them for comparative context: